Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus DEXONE 1 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus DEXONE 1 5.
BETAMETHASONE SODIUM PHOSPHATE vs DEXONE 1.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to suppress inflammation, immune response, and reduce capillary permeability.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
0.5-9 mg/day IV or IM in divided doses every 12-24 hours; acute conditions may require 4-8 mg IV initially.
1.5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 5-6 hours (plasma); biological half-life (HPA axis suppression): 24-36 hours.
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Renal: 90-95% as inactive metabolites; biliary/fecal: <5%.
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Category D/X
Category C
Corticosteroid
Corticosteroid